| Symbol |
CDK1 |
| Full Name |
Cyclin-Dependent Kinase 1 |
| Chromosome |
10q21.1 |
| NCBI Gene |
983 |
| Ensembl |
ENSG00000164946 |
| OMIM |
176741 |
| UniProt |
P06493 |
| Protein Class |
Serine/Threonine protein kinase |
| Molecular Function |
Protein kinase activity, ATP binding, cell cycle regulation |
| Diseases |
[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), Cancer, Neurodevelopmental disorders |
| Expression |
Ubiquitous ([neurons](/entities/neurons), glia, proliferating cells) |
CDK1 (Cyclin-Dependent Kinase 1) is a gene located on chromosome 10q21.1 that encodes a serine/threonine protein kinase essential for cell cycle progression. CDK1 is the catalytic subunit of the Maturation Promoting Factor (MPF) and is the sole CDK essential for G2/M transition and mitotic entry in all eukaryotic cells. In post-mitotic neurons, aberrant re-activation of CDK1 represents a key pathological mechanism in Alzheimer's Disease and Parkinson's Disease. The gene is catalogued as NCBI Gene ID 983, OMIM 176741, and UniProt P06493.
CDK1 is highly conserved across species and represents the founding member of the cyclin-dependent kinase family. Unlike other CDKs that function in specific cell cycle phases or transcriptional control, CDK1 can compensate for loss of other CDKs and is absolutely required for cell viability.
CDK1 is a proline-directed serine/threonine kinase that phosphorylates substrates containing the consensus sequence S/T-P-X-K/R. The kinase activity is tightly regulated by:
- Cyclin binding: CDK1 requires binding to cyclin B (primarily cyclin B1, encoded by CCNB1) for activity
- Phosphorylation: Wee1-mediated inhibitory phosphorylation at Tyr15 and Thr14 prevents premature mitotic entry; Cdc25 phosphatases remove these phosphates to activate CDK1
- Inhibitory phosphorylation: CDK inhibitors (p21CIP1, p27KIP1) can block CDK1 activity
CDK1 phosphorylates over 100 substrates involved in:
- Chromosome condensation: Histone H3 Ser10 phosphorylation
- Nuclear envelope breakdown: Lamin phosphorylation
- Spindle assembly: Microtubule-associated proteins
- Centrosome maturation: Pericentriolar material proteins
- DNA replication initiation: Origin recognition complex
CDK1 coordinates the G2/M transition through:
G2 Phase → Cyclin B accumulation → CDK1 activation
↓
Phosphorylation by Wee1 (inhibitory) ←→ Cdc25 (activating)
↓
Substrate phosphorylation → Mitotic entry
↓
APC/C activation → Cyclin B degradation → Mitotic exit
¶ Brain Expression and Localization
CDK1 exhibits unique expression patterns in the nervous system:
During CNS development, CDK1 is highly expressed in:
- Neural progenitor cells: Required for proliferation
- Migrating neurons: Active cell division
- Differentiating neurons: Temporal expression during neurogenesis
In mature neurons, CDK1 expression is dramatically reduced but not absent:
- Dendrites: Localized to dendritic spines, involved in synaptic plasticity
- Axon initial segment: Regulates neuronal polarity
- Synaptic terminals: Modulates neurotransmitter release
- Nuclear and cytoplasmic: Low-level expression maintains neuronal homeostasis
CDK1 is expressed in:
- Astrocytes: Moderate levels in proliferating astrocytes
- Microglia: Activated microglia show increased CDK1
- Oligodendrocyte progenitors: Required for myelination
Expression data is available from the Allen Brain Atlas.
One of the hallmark pathological features of neurodegenerative diseases is the inappropriate re-entry of post-mitotic neurons into the cell cycle. Since neurons are terminally differentiated and cannot divide, this re-entry leads to:
- Abortive cell cycle progression
- DNA replication stress
- Activation of apoptotic pathways
- Neuronal death
In Alzheimer's Disease, CDK1 re-activation is a consistent finding:
Pathological Evidence:
- CDK1/cyclin B complex is re-activated in vulnerable neurons
- Phosphorylation of CDK1 substrates (including Tau) increases
- Cell cycle markers (PCNA, Ki67) are detected in neurons
Mechanistic Links:
| AD Feature |
CDK1 Contribution |
| Amyloid-β toxicity |
Triggers CDK1 re-activation |
| Tau phosphorylation |
CDK1 phosphorylates Tau at disease-relevant sites |
| Synaptic loss |
CDK1 disrupts synaptic plasticity proteins |
| Neuronal death |
Abortive mitosis activates apoptosis |
CDK1-Mediated Tau Phosphorylation:
CDK1 phosphorylates Tau at multiple sites:
- Ser202/Thr205 (AT8 epitope)
- Thr212/Ser214
- Ser396
This hyperphosphorylated Tau aggregates into neurofibrillary tangles.
In Parkinson's Disease, CDK1 involvement is evident in:
Dopaminergic neuron vulnerability:
- CDK1 re-activation in substantia nigra neurons
- Links to α-synuclein phosphorylation at Ser129
Mechanistic pathways:
- α-Synuclein phosphorylation: CDK1 phosphorylates α-synuclein at Ser129, promoting aggregation
- Mitochondrial dysfunction: CDK1 affects mitochondrial dynamics proteins
- Autophagy disruption: CDK1 modulates autophagy initiation
- Oxidative stress response: Cell cycle proteins respond to oxidative DNA damage
Therapeutic implications:
- CDK1 inhibitors protect dopaminergic neurons
- CDK1 modulation restores autophagy
CDK1 contributes to AD pathogenesis through multiple mechanisms:
- Tau pathology: CDK1-mediated Tau hyperphosphorylation
- Amyloid-β response: Aβ triggers CDK1 activation
- Synaptic dysfunction: CDK1 disrupts synaptic proteins
- Neuronal apoptosis: Abortive cell cycle leads to death
In PD, CDK1 plays distinct roles:
- α-Synuclein phosphorylation: Ser129 phosphorylation by CDK1
- Mitochondrial dynamics: CDK1 affects mitophagy proteins
- Dopaminergic neuron survival: CDK1 inhibition is protective
CDK1 is a major therapeutic target in cancer:
- Required for tumor cell proliferation
- Amplified/overexpressed in multiple cancers
- CDK1 inhibitors in clinical trials
Altered CDK1 function affects:
- Brain development: Abnormal progenitor proliferation
- Neuronal migration: Cytoskeletal regulation
- Synaptogenesis: Post-mitotic synaptic development
Several CDK1 inhibitors have shown promise:
| Inhibitor |
Status |
Application |
| RO-3306 |
Research |
Reversible CDK1 inhibition |
| AZD5438 |
Clinical trials |
Pan-CDK inhibitor |
| Flavopiridol |
Clinical trials |
Broad CDK inhibition |
Therapeutic considerations:
- Timing: Early intervention may be most effective
- Selectivity: CDK1-specific vs. pan-CDK approaches
- Blood-brain barrier penetration required
CDK1 inhibition may synergize with:
- Amyloid-β targeted therapies: Reduces toxicity-driven re-entry
- Tau-based treatments: Decreases pathological phosphorylation
- Antioxidants: Addresses oxidative stress trigger
CDK1 activity markers:
- Phospho-Tau levels in CSF
- Cell cycle proteins in peripheral blood
- Imaging markers of neuronal proliferation
CDK1 interacts with:
- Wee1: Inhibitory kinase
- Cdc25C: Activating phosphatase
- Chk1/Chk2: DNA damage checkpoint kinases
- PKA/PKC: Cross-talk kinases
- Cyclin B1 (CCNB1): Primary activating cyclin
- Cyclin A: Earlier cell cycle phases
- Cyclin E: G1/S transition
Key neuronal substrates:
- Tau (MAPT): Microtubule-associated protein
- Synapsin: Synaptic vesicle regulation
- MAP1B: Axonal growth
- p53: Apoptosis regulation
- What triggers CDK1 re-activation in neurons?
- Is CDK1 re-entry cause or consequence of neurodegeneration?
- Can CDK1 inhibition restore neuronal function?
- What determines regional vulnerability (why substantia nigra in PD, hippocampus in AD)?
- Single-cell analysis of CDK1 in AD/PD brains
- Patient-derived neurons for drug screening
- CDK1 substrate mapping in neurodegenerative contexts
- Gene therapy approaches targeting CDK1 pathways